It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Recent successes in developing small molecule degraders that act through the ubiquitin system have spurred efforts to extend this technology to other mechanisms, including the autophagosomal-lysosomal pathway. Therefore, reports of autophagosome tethering compounds (ATTECs) have received considerable attention from the drug development community. ATTECs are based on the recruitment of targets to LC3/GABARAP, a family of ubiquitin-like proteins that presumably bind to the autophagosome membrane and tether cargo-loaded autophagy receptors into the autophagosome. In this work, we rigorously tested the target engagement of the reported ATTECs to validate the existing LC3/GABARAP ligands. Surprisingly, we were unable to detect interaction with their designated target LC3 using a diversity of biophysical methods. Intrigued by the idea of developing ATTECs, we evaluated the ligandability of LC3/GABARAP by in silico docking and large-scale crystallographic fragment screening. Data based on approximately 1000 crystal structures revealed that most fragments bound to the HP2 but not to the HP1 pocket within the LIR docking site, suggesting a favorable ligandability of HP2. Through this study, we identified diverse validated LC3/GABARAP ligands and fragments as starting points for chemical probe and ATTEC development.
Autophagosome tethering compounds (ATTECs) are small molecule degraders hijacking the autophagy system. Here, the authors show that current ATTEC ligands did not bind to their designated targets but establish good ligandability of ATG8 isoforms through fragment screening and docking.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Dopfer, Johannes 2
; Kumar, Adarsh 2
; Greco, Francesco A. 2
; Bauer, Nicolas 2
; Löhr, Frank 3
; Heering, Jan 4
; Cano-Franco, Sara 5
; Lechner, Severin 6
; Hanke, Thomas 2
; Jaser, Ivana 7
; Morasch, Viktoria 2
; Lenz, Christopher 2
; Fearon, Daren 8
; Marples, Peter G. 8
; Tomlinson, Charles W. E. 8
; Brunello, Lorene 5
; Saxena, Krishna 2
; Adams, Nathan B. P. 7
; von Delft, Frank 8
; Müller, Susanne 2
; Stolz, Alexandra 5
; Proschak, Ewgenij 9
; Kuster, Bernhard 6
; Knapp, Stefan 1
; Rogov, Vladimir V. 2
1 Goethe University Frankfurt, Institute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); Goethe University Frankfurt, Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); DKTK site Frankfurt-Mainz, German Cancer Consortium (DKTK) / German Cancer Research Center (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
2 Goethe University Frankfurt, Institute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); Goethe University Frankfurt, Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721)
3 Goethe University Frankfurt, Institute for Biophysical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721)
4 Theodor-Stern-Kai 7, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany (GRID:grid.510864.e)
5 Goethe University, Institute of Biochemistry II (IBC2), Faculty of Medicine, Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); Goethe University, Buchmann Institute for Molecular Life Sciences (BMLS), Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721)
6 Technical University of Munich, Chair of Proteomics and Bioanalytics, TUM School of Life Sciences, Freising, Germany (GRID:grid.6936.a) (ISNI:0000 0001 2322 2966)
7 NanoTemper Technologies GmbH, Munich, Germany (GRID:grid.511332.7) (ISNI:0000 0004 4659 2945)
8 Harwell Science and Innovation Campus, Diamond Light Source Ltd., Didcot, UK (GRID:grid.18785.33) (ISNI:0000 0004 1764 0696)
9 Goethe University Frankfurt, Institute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); Theodor-Stern-Kai 7, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany (GRID:grid.510864.e)




